Quanta Announces IND Clearance by U.S. FDA for QTX3544, an Oral G12V-Preferring Multi-KRAS Inhibitor, and Other Pipeline Updates
Additionally, the Phase 1 clinical trial evaluating QTX3034, an oral G12D-preferring multi-KRAS inhibitor, as a monotherapy and in combination with cetuximab, continues to enroll patients, and data is ...
Tumor-secreted protein may hold the key to better treatments for deadly brain tumor
A study co-led by UCLA scientists has found targeting a protein called endocan and its related signaling pathway could be a ...
Unborn Babies Use Genes From Dad to “Remote-Control” Mothers for Extra Food
Scientists at Cambridge have unveiled a fascinating mechanism where fetuses use a paternal gene to control the mother's ...